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Undesirable physicochemical properties of amine, peptide and peptidomimetic drugs often result in their low membrane permeabilities through the biological barriers and, therefore, low bioavailabilities. [1] [2] [3] [4] Prodrug strategy 5) represents a promising approach to modifying the undesirable physicochemical properties of such drugs to aid in their delivery to the desired site of action. 1, 2) However, the preparation of prodrugs of amines, peptides, and peptidomimetics is often challenging due to the complexity of peptide molecules and the lack of appropriate chemical method to bioreversibly derivatize an amino group. 6 ) Recently, our laboratory has developed a novel coumarin-based prodrug system for the preparation of esterase-sensitive prodrugs of amines, [7] [8] [9] [10] peptides, [11] [12] [13] and peptidomimetics, [14] [15] [16] which are otherwise difficult to make. 1, 2, 6) The design takes advantage of the spontaneous lactonization of cis-coumarinic acid and its derivatives 2 (Chart 1). [17] [18] [19] In such a strategy, a latent nucleophile can be unmasked using an esterase triggering mechanism that initiates a lactonization reaction to release the parent drug (Chart 1). Using this prodrug strategy, we have prepared esterasesensitive prodrugs of model amines (Chart 1), [7] [8] [9] [10] esterasesensitive cyclic prodrugs (Chart 2) of opioid peptides [11] [12] [13] and peptidomimetic glycoprotein IIb/IIIa antagonists [14] [15] [16] with greatly improved membrane permeability. We have also prepared an esterase-sensitive cyclic prodrug of tirofiban, [20] [21] [22] [23] [24] an FDA approved antithrombotic drug which can only be administered through the i.v. route. The coumarin-based prodrug of tirofiban, showed greatly improved oral bioactivities in preliminary studies in dogs, 15) further demonstrating the clinical potential of this coumarin-based prodrug approach. Now that we have demonstrated the clinical potential of this prodrug system, it will be important for us to address one practical issue, i.e., the ability to fine-tune the release rates so that the release time profile can be modulated to suit the need of individual drugs. In our earlier studies, we have found that the release rates are largely dictated by the rate of lactonization (2 to 3, Chart 1), which in turn depends on the structural features of the drug moieties. 7, 9) The release rates are affected by the pK a and the steric features of the amines to be released. 9) Amines with lower pK a 's tend to be released at faster rates. Steric hindrance on the amine part tends to slow down the release. Ideally, one would like to be able to modulate the release rates independent of the structural properties of the drug moiety. In order to find ways to modulate the release rates of this class of prodrugs, it is important that we achieve a basic understanding of the factors that could affect the release rates. Since both the acyl moiety and the amine moiety are integral components of the drug moiety in a cyclic prodrug system (Chart 2), our focus shifted to the effect of phenyl ring substitutions. There have been ample literature precedents indicating that ring substituents, which introduce steric congestion, could be used for modulating the rates of lactonization reactions. [17] [18] [19] [25] [26] [27] [28] [29] Aimed at understanding the structure-release rate relationship of the coumarin-based prodrugs, a series of substituted coumarinic acid derivatives were synthesized. The release rates of these prodrugs were studied using porcine liver esterase (PLE) in phosphate buffer solution at pH 7.4. It was found that introduction of methyl substitutions ortho to the alkyl side chain and the phenol hydroxyl group results in significant increases in release rates.
Results and Discussion
For this study, we have designed a series of compounds with methyl substitutions at different positions of the phenyl ring to achieve a thorough understanding of the effect of alkyl substitution on the release kinetics. N-Methylbenzylamine and diethylamine were used as the model amines for the study.
Synthesis We have developed three approaches to the synthesis of coumarin-based prodrugs. 30) For this study, we chose to use the approach starting with substituted coumarins because of the ready availability of these compounds either commercially or synthetically. Substituted coumarins 3g-i are commercially available. However, compounds 3a-f need to be synthesized. There are several procedures reported for the preparation of substituted coumarins using methods ranging from palladium-catalyzed addition 31) to Wittig reactions [32] [33] [34] [35] and other reactions. [36] [37] [38] We took a Friedel-Crafts type of reaction approach for the synthesis of substituted coumarins 3a-f by heating the corresponding substituted phenol 5a-f with propiolic acid or its ester in methanesulfonic acid to give the desired substituted coumarins 3a-f in 40-90% yields (Chart 3). We studied this reaction using both propiolic acid and its methyl ester and found that both gave similar yields. Then the substituted coumarins (3a-i) were reduced using lithium aluminum hydride (LAH) at 0°C to give the ring-opened diols 6a-i in about 30-55% yields. The primary hydroxyl groups of diols 6a-i were selectively protected as a silyl ether by reacting with tert-butyldimethyl silyl (TBDMS) chloride to give 7 in 80-90% yields. The acetylation of the free phenol hydroxyl group of 7 was accomplished by reaction with acetic anhydride in the presence of triethylamine (TEA) and 4-dimethylaminopyridine (DMAP) in about 90% yields. The free primary hydroxyl group of 9 after deprotection of the silyl group using acetic acid was converted to the carboxyl group in two steps. The oxidation to the aldehydes 10 was accomplished using manganese dioxide in dichloromethane (DCM) in about 90% yield. Conversion of the aldehydes 10 to the carboxylic acids 11 was accomplished in 60-100% yield by oxidation with sodium chlorite in the presence of hydrogen peroxide under acidic conditions. The free acids 11 were then coupled with N-methylbenzylamine or diethylamine using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) as the activating reagent in the presence of hydroxybenzotriazole (HOBt) and DMAP to give the model prodrugs 1a-r.
Esterase Kinetics The esterase kinetic studies were carried out following procedures reported earlier using PLE.
7,9,11) Briefly the reaction was followed with UV. Upon incubation with PLE in phosphate buffer (0.05 M, pH 7.4, 37Ϯ0.5°C) at an enzyme concentration of about 1 unit/ml, all model prodrugs 1a-r completely released the amine moiety as designed. Figure 1 shows a typical set of UV spectra in a kinetic study. The pseudo first order rate constants were determined from linear curve-fittings. Data from the first 4-5 half-lives were used. Figure 2 shows some typical plots used for the determination of the rate constants. The objectives of this study were to see how alkyl substitutions on the phenyl ring would affect the release rates and whether such substitutions could help to enhance the release rates as designed. As shown in Tables 1 and 2 , with the monomethyl or dimethyl substituted model prodrug systems 1a-l with at least one methyl group vicinal to either the side chain alkenyl group or the phenol hydroxyl group, significant release rate enhancements were observed compared with the un-substituted model prodrugs 1s and 1t. For example, the release rates for N-methylbenzylamine in the coumarin-based model prodrug system 1s 7,9) (R 1 ϭR 2 ϭR 3 ϭR 4 ϭH) had a halflife of about 32 min (Table 1) . With the dimethyl-substituted model prodrug systems 1a, which has one methyl group next to the side chain alkenyl group and one methyl group next to the phenol hydroxyl group, the release was about 5-fold faster with a half-life of 4.8 min. This is not surprising. There have been literature precedents indicating that the steric hindrance at both positions facilitates similar lactonizations. 27, 28, 39, 40) It is also logical that with only one substituent at either of the two vicinal position (R 1 and R 4 ) a significant increase in the release rates was observed, however, to a lesser degree compared with the di-substituted ones. For example, compounds 1c, 1g, and 1i had release half-lives ranging from 6.3-8.5 min, which are significantly shorter than that of the unsubstituted one 1s (32 min), but slightly longer than that of 1a (4.8 min). One unexpected result was with compound 1e, which has R 1 and R 2 as methyl groups. It has a half-life of about 3.2 min which is shorter than that of 1a and has only one methyl substituent next to the phenol hydroxyl group. It is conceivable that the R 2 methyl group could help to facilitate the lactonization through either electronic or steric effect or a combination of both. As an electron donating group, the R 2 methyl group is expected to decrease the electrophilicity of the amide carbonyl and increase the charge on the phenol hydroxyl oxygen. To examine the effect of the R 2 substituent alone, we have also synthesized and evaluated compounds 1o and 1q, with a methyl and a methoxy group at the R 2 position, respectively. With a single electron donating group (methyl or methoxy) at the R 2 position, the release rates of 1o and 1q were similar to that of the unsubstituted compound 1s. This suggests that the electronic effect of the R 2 substituent is minimal even with a strongly electron donating methoxy group at the R 2 position. Then the unexpected rate enhancement for 1e is most likely due to the enhanced steric congestion introduced by the R 2 group next to R 1 . However, similar effect was not observed when an additional methyl group was positioned next to R 4 (1k), which did not further enhance the release rate of compound 1c. The effect of R 3 alone (1m) was also examined as a control and R 3 alone was found to have very little effect on the lactonization rate. All of these are consistent with steric factors being the predominant factors in determining the reaction rates.
The same study was also carried out with the release of diethylamine for two reasons. First, we would like to confirm that the substituent effect observed with the release of methylbenzylamine is generally applicable. Second, the release of diethylamine is much slower than that of methylbenzylamine, which would help to "spread out" the data so that experimental errors would not complicate the data interpretation as much. For example, the maximum t 1/2 difference for the release of methylbenzylamine among all the analogs (1a-k) with at least one methyl group ortho to either the alkene side chain or the phenol ester was less than 5 min. Minor experimental errors could significantly affect the outcome of the interpretation. With the corresponding diethylamine analogs (1b-l), the maximum difference in t 1/2 was about 35 min. Again, the highest release rates were observed with the methyl group at the R 1 and R 4 (1b, t 1/2 ϭ11.4 min) or R 1 and R 2 (1f, t 1/2 ϭ11.9 min) positions. The release rates were significantly slower with other substituted coumarinic acid analogs with only one methyl group next to either the side chain alkenyl or phenol hydroxyl group. For example, the releases rates of 1d, 1h, 1j, and 1l ranged from 18.8 to 46.4 min. However, all these substituted analogs released diethylamine at a much faster rates than that of the unsubstituted one 1t, which has a half-life of about 188 min. 7, 9) Similarly, mono-substitution at either R 2 or R 3 position alone had very little effect on the release rates. For example, the halflives of 1n, 1p, and 1r ranged from 197 to 214 min compared with the half-life of 188 min of the unsubstituted one (1t).
Therefore, the steric effect of the substituents ortho to either the side chain alkenyl group or the phenol carboxyl group is the most important factor in determining the lactonization rates of the substituted coumarinic acid derivatives. Electronic factors by substituents at the R 2 and R 3 position seem to have very little effect on the lactonization rates.
Conclusions
Aimed at understanding the structure-release rate relationship, we have designed, synthesized, and evaluated a series of substituted coumarinic acid analogs. Their esterase-catalyzed release rates have been studied using PLE. It was found that methyl substituents ortho to either the side chain alkenyl group or the phenol carboxyl group can greatly enhance the rate of lactonization of such systems through the introduction of steric congestion. The electronic effect of the substituents at the R 2 and R 3 positions are not important in influencing the release rates. The understanding of the structure-release rate relationship will help the design of prodrugs with different release time profiles.
Experimental
General Methods All 1 H-NMR spectra were recorded at 300 MHz with TMS as the internal standard. Column chromatography was performed using silica gel (200-400 mesh) from Aldrich. Elemental analyses were performed by Atlantic Microlab Inc. Mass spectral analyses were conducted by North Carolina State University Mass Spectrum Laboratory. Commercially available starting materials and reagents were purchased from Aldrich. THF was distilled from Na and benzophenone; methylene chloride (CH 2 Cl 2 ) was distilled from CaH 2 . A Shimadzu 1601 UV-visible spectrophotometer was used for the esterase kinetics study. 41) To a solution of 2,5-dimethyl phenol (5a) (2.440 g, 20 mmol) in methansulfonic acid (40 ml) was added propiolic acid (1.479 ml, 24 mmol) at room temperature. After stirring at 85-90°C under N 2 atmosphere for 4 h, the solution was diluted with 80 ml de-ionized water and extracted with 120 ml ethyl acetate (40 mlϫ3). The ethyl acetate layer was washed with saturated Na 2 CO 3 (30 mlϫ3) and then saturated NaCl, and dried over MgSO 4 and concentrated to give a gray solid (3.123 g, 81%). 
5,8-Dimethylcoumarin (3a)

2-[(Z)-3-Hydroxy-1-propenyl]-3,6-dimethylphenol (6a)
A solution of 5,8-dimethyl coumarin (3a) (2.453 g, 14.1 mmol) in ether (60 ml) was treated at 0°C with a suspension of LAH (1.072 g, 28.2 mmol) in ether (20 ml). After stirring for 15 min, 1 N HCl (85 ml) was added to dropwise the reaction at 0°C. Then the solution was extracted with ether (3ϫ100 ml). The combined ether layers was dried over MgSO 4 and concentrated to give a light yellow solid (2.431 g). Recrystallization from methylene chloride/ethyl acetate (7 : 1) gave 6a (1.325 g, 52%) as gray white crystals: 1 
2-[(Z)-3-{[1-(tert-Butyl)-1,1-dimethyl-silanyl]oxy}-1-propenyl]-3,6-dimethylphenol (7a)
To the stirred solution of 6a (1.198 g, 10.1 mmol) in dry THF (15 ml), the solution of tert-butyldimethylsilyl chloride (2.273 g, 15.2 mmol) in dry THF (30 ml) was added at 0°C, followed by the dropwise addition of DMAP (1.838 g, 38.7 mmol) in dry THF (20 ml). After stirring at 0°C for 8 h, the solution was filtered and evaporated to remove the THF. Ethyl acetate (50 ml) was added and the solution was washed with 1 N HCl (3ϫ20 ml), 5% NaHCO 3 (2ϫ20 ml) and water (20 ml 2 Cl 2 (30 ml) was added dropwise acetic anhydride (0.808 ml, 7.32 mmol), DMAP (149 mg, 1.22 mmol) and TEA (1.56 ml, 11 mmol). After stirring at room temperature under N 2 atmosphere for 1 h, the reaction mixture was washed with 1 N HCl (2ϫ20 ml), 5% NaHCO 3 (15 ml) and water (15 ml 2-[(Z)-3-Hydroxy-1-propenyl]-3,6-dimethylphenyl Acetate (9a) To the solution of 8a (1.425 g, 4.27 mmol) in THF (12 ml) was added water (12 ml) and then added dropwise acetic acid (36 ml). The mixture was stirred at room temperature for 3 h and then evaporated to remove THF, water and acetic acid. Ethyl acetate (50 ml) was added to the residue, which was washed with 5% NaHCO 3 (3ϫ20 ml) and water (2ϫ20 ml). It was dried over MgSO 4 , filtered and evaporated to afford 9a as a white oil (931 mg, 100% (Z)-3-[2-(Acetyloxy)-3,6-dimethylphenyl]acrylic Acid (11a) A solution of 80% sodium chlorite (210 mg, 2.1 mmol) in water (1.86 ml) was added dropwise in 2 h to a stirred mixture of 10a (252 mg, 1.09 mmol) in acetonitrile (1.33 ml), sodium phosphate (43 mg) in water (0.53 ml), and 30% hydrogen peroxide (0.156 ml), while its temperature was kept at 10°C with an ice-water bath. Oxygen evolution from the solution was monitored until the end of the reaction (about 2 h) with a bubbler connected to the apparatus. A small amount of sodium sulfite was added to destroy the unreacted HOCl and H 2 O 2 . The solution was acidified with 1 N HCl to pHϭ1-2. The mixture was extracted with ethyl acetate (30 ml). The ethyl acetate layer was washed with saturated sodium chloride solution (2ϫ30 ml) and dried over MgSO 4 . Filtration and evaporation of the solvent afforded 11a as a white solid (244 mg, 96% 
2-[(Z)-2-(Benzylmethylcarbamoyl)vinyl]-3,6-dimethylphenyl Acetate (1a)
To the solution of 11a (220 mg, 0.94 mmol) in dry CH 2 Cl 2 (5 ml) was added EDC (217 mg, 1.128 mmol) at 0°C. The mixture was stirred for 10 min. To the mixture was added dropwise methyl benzylamine (0.145 ml, 1.128 mmol) and DMAP (23 mg, 0.189 mmol). After stirring at 0°C under N 2 atmosphere for 1 h, the ice bath was withdrawn and the reaction was kept stirring at room temperature for 3 h. Then CH 2 Cl 2 (50 ml) was added. The CH 2 Cl 2 layer was washed with saturated NaHCO 3 solution (3ϫ20 ml), 10% citric acid solution (2ϫ20 ml) and water (20 ml), and dried over MgSO 4 . Filtration and evaporation gave a light yellow oil, which was chromatographed on a silica gel column with ethyl acetate/hexane (1 : 4) to give 1a as a white solid (253 mg, 72% 
2-[(Z)-2-(Diethylcarbamoyl-vinyl]-3,6-dimethylphenyl Acetate (1b)
To the solution of 11a (318 mg, 1.36 mmol) in dry CH 2 Cl 2 (10 ml) was added EDC (261 mg, 1.36 mmol) at 0°C, The mixture was stirred for 10 min. To the mixture was added dropwise diethylamine (0.168 ml, 1.63 mmol), HOBt (183 mg, 1.36 mmol) and DMAP (33 mg, 0.272 mmol). After stirring at 0°C under N 2 atmosphere for 1 h, the ice bath was withdrawn and the reaction was kept stirring at room temperature for 3 h. Then CH 2 Cl 2 (50 ml) was added. The CH 2 Cl 2 layer was washed with saturated NaHCO 3 solution (3ϫ20 ml), 10% citric acid solution (2ϫ20 ml) and water (20 ml), and dried over MgSO 4 . Filtration and evaporation gave a light yellow oil, which was chromatographed on a silica gel column with ethyl acetate/hexane (1 : 4) to give 1b as a white solid (304 mg, 66% 42) In a manner similar to the preparation of 3a, 3,5-dimethyl phenol (5b) (2.196 g, 18 mmol) and propiolic acid (1.331 ml, 21.6 mmol) were reacted in methansulfonic acid (40 ml) to give 3b as a gray solid (2.184 g, 68% 
2-[(Z)-3-Hydroxy-1-propenyl]-3,5-dimethylphenyl Acetate (9b)
In a manner similar to the preparation of 9a, 8b (902 mg, 2.68 mmol, in 10 ml dry THF), water (10 ml) and acetic acid (30 ml) were reacted to give 9b as a white oil (622 mg, 100%). (
Z)-3-[2-(Acetyloxy)-4,6-dimethylphenyl]acrylic Acid (11b)
In a manner similar to the preparation of 11a, 80% sodium chlorite (348 mg, 3.87 mmol) in water (3.10 ml), 10b (402 mg, 1.09 mmol, in 2.2 ml acetonitrile), sodium phosphate (69 mg) in water (0.85 ml), and 30% hydrogen peroxide (0.156 ml) were reacted to give 11b as a white solid (422 mg, 98% 43) In a manner similar to the preparation of 3a, 1,2-dimethyl phenol (5c) (2.440 g, 20 mmol) and propiolic acid (1.476 ml, 24 mmol) were reacted in methansulfonic acid (40 ml) to give 3c as a gray solid (3.192 g, 90%) . 1 
2-[(Z)-2-(Benzylmethylcarbamoyl)-vinyl]-3,5-dimethylphenyl
6-[(Z)-3-{[1-(tert-Butyl)-1,1-dimethylsilanyl]oxy}-1-propenyl]-2,3-dimethylphenol (7c)
In a manner similar to the preparation of 7a, 6c (628 mg, 3.451 mmol, in 10 ml dry THF), tert-butyldimethylsilyl chloride (569 mg, 3.796 mmol, in 5 ml dry THF), and DMAP (632 mg, 5.177 mmol, in 10 ml dry THF) were reacted to give 7c as a white solid (807 mg, 80%). 1 
6-[(Z)-3-Hydroxy-1-propenyl]-2,3-dimethylphenyl Acetate (9c)
In a manner similar to the preparation of 9a, 8c (216 mg, 0.643 mmol, in 2.4 ml dry THF), water (2.4 ml) and acetic acid (7.2 ml) were reacted to give 9c as a white oil (142 mg, 100% 2-(Benzylmethylcarbamoyl)-vinyl]-2,3- 44) In a manner similar to the preparation of 3a, 2,4-dimethyl phenol (5d) (2.440 g, 18 mmol) and propiolic acid (1.479 ml, 24 mmol) were reacted in methansulfonic acid (40 ml 
6-[(Z)-
2-[(Z)-3-Hydroxy-1-propenyl]-4,6-dimethylphenol (6d)
In a manner similar to the preparation of 6a, 6,8-dimethyl coumarin (3d) (2.4532 g, 14.1 mmol) in ether (60 ml) was treated with a suspension of LAH (1.072 g, 28.2 mmol) in ether (20 ml) to afford 6d (986 mg, 38%) as gray white crystals. 
2-[(Z)-3-{[1-(tert-Butyl)-1,1-dimethyl-silanyl]oxy}-1-propenyl]-4,6-dimethylphenol (7d)
In a manner similar to the preparation of 7a, 6d (926 mg, 5.10 mmol, in 15 ml dry THF), tert-butyldimethylsilyl chloride (840 mg, 5.60 mmol, in 30 ml dry THF) and DMAP (933 mg, 7.60 mmol, in 20 ml dry THF) were reacted to give 7d as a white solid (1.280 g, 84%) . 
2-[(Z)-3-Hydroxy-1-propenyl]-4,6-dimethylphenyl Acetate (9d)
In a manner similar to the preparation of 9a, 8d (1.298 mg, 3.863 mmol, in 22 ml dry THF), water (22 ml) and acetic acid (65 ml) were reacted to give 9d as a white oil (838 mg, 99%). In a manner similar to the preparation of 11a, 80% sodium chlorite (459 mg, 5.10 mmol) in water (4.08 ml), 10d (530 mg, 2.43 mmol, in 2.9 ml acetonitrile), sodium phosphate (43 mg) in water (1.1 ml), and 30% hydrogen peroxide (0.35 ml) were reacted to give 11d as a white solid (550 mg, 97%). 
2-[(Z)-2-(Benzylmethylcarbamoyl)-vinyl]-4,6-dimethylphenyl Acetate (1g)
In a manner similar to the preparation of 1a, 11d (275 mg, 1.175 mmol, in 10 ml dry CH 2 Cl 2 ), EDC (225 mg, 1.175 mmol), methyl benzylamine (0.182 ml, 1.41 mmol), and DMAP (28 mg, 0.235 mmol) were reacted to give 1g as a white solid (264 mg, 78% a manner similar to the preparation of 1b, 11d (275 mg, 1.175 45) In a manner similar to the preparation of 3a, o-methylphenol (5e) (3.240 g, 30 mmol) and propiolic acid (2.488 ml, 36 mmol) were reacted in methansulfonic acid (30 ml 
2-[(Z)-3-{[1-(tert-Butyl)-1,1-dimethyl-silanyl]oxy}-1-propenyl]-6-methylphenol (7e)
In a manner similar to the preparation of 7a, 6e (142 mg, 0.87 mmol, in 6 ml dry THF), tert-butyldimethylsilyl chloride (143 mg, 0.95 mmol, in 3 ml dry THF) and DMAP (159 mg, 1.31 mmol, in 3 ml dry THF) were reacted to give 7e as a white solid (176 mg, 73%). (Z)-3-[2-(Acetyloxy)-4,5,6-trimethylphenyl]acrylic Acid (11f) In a manner similar to the preparation of 11a, 80% sodium chlorite (28 mg, 0.308 mmol) in water (0.220 ml), 10f (32 mg, 0.147 mmol, in 0.2 ml acetonitrile), sodium phosphate (6.0 mg) in water (0.060 ml), and 30% hydrogen peroxide (0.020 ml) were reacted to give 11f as a white solid (35 mg, 96%). 16 (3H, s), 2.19 (3H, s), 2.23 (3H, s), 2.28 (3H, s) 
2-[(Z)-3-Hydroxy-1-propenyl]-4-methylphenol (6g)
In a manner similar to the preparation of 6a, 6-methylcoumarin (3g) (8.02 g, 50 mmol) in ether (200 ml) was treated with a suspension of LAH (3.79 g, 100 mmol) in ether (100 ml) to afford 6g (2.50 g, 30%) as white crystals. 
2-[(Z)-3-{[1-(tert-Butyl)-1,1-dimethylsilanyl]oxy}-1-propenyl]-4-methylphenol (7g)
In a manner similar to the preparation of 7a, 6g (630 mg, 3.8 mmol, in 5.9 ml dry THF), tert-butyldimethylsilyl chloride (640 mg, 4.2 mmol, in 4.4 ml dry THF) and DMAP (700 mg, 5.7 mmol, in 7.4 ml dry THF) were reacted to give 7g as a white solid (880 mg, 83%). 
2-[(Z)-3-Hydroxy-1-propenyl]-4-methylphenyl Acetate (9g)
In a manner similar to the preparation of 9a, 8g (960 mg, 2.68 mmol, in 8.5 ml dry THF), water (8.5 ml) and acetic acid (25.5 ml) were reacted to give 9g as a yellow oil (640 mg, 100%). 
